Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Felice Rivellese

Showing results (51-60 of 62) with videos related to

Pageof 7
Sort By:
Nature Medicine|May 19, 2022
Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trialFelice Rivellese, Anna E A Surace, Katriona Goldmann, et al.
Annals of the Rheumatic Diseases|February 25, 2022
EULAR points to consider for minimal reporting requirements in synovial tissue research in rheumatologyAurélie Najm, Félicie Costantino, Stefano Alivernini, et al.
Annals of the Rheumatic Diseases|September 23, 2020
Unique expansion of IL-21+ Tfh and Tph cells under control of ICOS identifies Sjögren's syndrome with ectopic germinal centres and MALT lymphomaElena Pontarini, William James Murray-Brown, Cristina Croia, et al.
Nature Medicine|July 18, 2017
Resolution of inflammation by interleukin-9-producing type 2 innate lymphoid cellsSimon Rauber, Markus Luber, Stefanie Weber, et al.
Lancet (London, England)|January 24, 2021
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trialFrances Humby, Patrick Durez, Maya H Buch, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 10, 2023
Serum and Tissue Biomarkers Associated With Composite of Relevant Endpoints for Sjögren Syndrome (CRESS) and Sjögren Tool for Assessing Response (STAR) to B Cell-Targeted Therapy in the Trial of Anti-B Cell Therapy in Patients With Primary Sjögren Syndrome (TRACTISS)Elena Pontarini, Elisabetta Sciacca, Farzana Chowdhury, et al.
Cell Reports|August 29, 2019
Molecular Portraits of Early Rheumatoid Arthritis Identify Clinical and Treatment Response PhenotypesMyles J Lewis, Michael R Barnes, Kevin Blighe, et al.
The Lancet. Rheumatology|January 22, 2024
Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trialsFelice Rivellese, Alessandra Nerviani, Giovanni Giorli, et al.
Autoimmunity Reviews|December 16, 2020
The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts' ConsensusRoberto Giacomelli, Antonella Afeltra, Elena Bartoloni, et al.
Nature|November 8, 2023
Deconstruction of rheumatoid arthritis synovium defines inflammatory subtypesFan Zhang, Anna Helena Jonsson, Aparna Nathan, et al.
Pageof 7

Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
Nature Medicine|May 19, 2022
Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trialFelice Rivellese, Anna E A Surace, Katriona Goldmann, et al.
Annals of the Rheumatic Diseases|February 25, 2022
EULAR points to consider for minimal reporting requirements in synovial tissue research in rheumatologyAurélie Najm, Félicie Costantino, Stefano Alivernini, et al.
Annals of the Rheumatic Diseases|September 23, 2020
Unique expansion of IL-21+ Tfh and Tph cells under control of ICOS identifies Sjögren's syndrome with ectopic germinal centres and MALT lymphomaElena Pontarini, William James Murray-Brown, Cristina Croia, et al.
Nature Medicine|July 18, 2017
Resolution of inflammation by interleukin-9-producing type 2 innate lymphoid cellsSimon Rauber, Markus Luber, Stefanie Weber, et al.
Lancet (London, England)|January 24, 2021
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trialFrances Humby, Patrick Durez, Maya H Buch, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 10, 2023
Serum and Tissue Biomarkers Associated With Composite of Relevant Endpoints for Sjögren Syndrome (CRESS) and Sjögren Tool for Assessing Response (STAR) to B Cell-Targeted Therapy in the Trial of Anti-B Cell Therapy in Patients With Primary Sjögren Syndrome (TRACTISS)Elena Pontarini, Elisabetta Sciacca, Farzana Chowdhury, et al.
Cell Reports|August 29, 2019
Molecular Portraits of Early Rheumatoid Arthritis Identify Clinical and Treatment Response PhenotypesMyles J Lewis, Michael R Barnes, Kevin Blighe, et al.
The Lancet. Rheumatology|January 22, 2024
Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trialsFelice Rivellese, Alessandra Nerviani, Giovanni Giorli, et al.
Autoimmunity Reviews|December 16, 2020
The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts' ConsensusRoberto Giacomelli, Antonella Afeltra, Elena Bartoloni, et al.
Nature|November 8, 2023
Deconstruction of rheumatoid arthritis synovium defines inflammatory subtypesFan Zhang, Anna Helena Jonsson, Aparna Nathan, et al.
Pageof 7